公开(公告)号：US20020006378A1

公开(公告)日：2002-01-17

申请号：US08975090

申请日：1997-11-20

Inventor： STUART W. YOUNG ,  MEREDITH WRIGHT ,  JONATHAN L. SESSLER ,  TARAK D. MODY ,  DARREN MAGDA

IPC: C07F001/00 ,  C07D201/00 ,  A61M036/14 ,  A61K051/00 ,  A61B005/055 ,  C09B047/00 ,  C07D213/00 ,  A61K049/04 ,  A61B010/00

CPC classification number: B82Y5/00 ,  A61K41/0076 ,  A61K47/554 ,  A61K47/6901 ,  A61K47/6911 ,  A61K49/085 ,  A61K49/1896

Abstract: Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen. By presenting the agent in this way, it is expected that a patient will experience less toxicity.

Abstract translation: 提供了具有加载到生物囊泡中的泰克萨菲瑞 - 亲脂性分子缀合物的组合物以及使用加载的囊泡进行成像，诊断和治疗的方法。 例如，装载有顺磁性泰克萨菲瑞 - 亲脂性分子缀合物的脂质体或红细胞具有作为血液池造影剂的效用，有利于正常组织的增强，磁共振血管造影术，以及通过开窗口或损伤引起的出血损伤的内皮标记区域 部分血管系统。 可以光密化具有感光性泰克萨菲瑞 - 亲脂性分子缀合物的脂质体或细胞，从而在裂解部位产生光动力学治疗效果。 载有感光性泰克萨菲瑞 - 亲脂性分子缀合物的红细胞的可获得性提供了一种将光动力治疗剂递送至具有高浓度氧的所需部位的方法。 通过以这种方式呈现代理，预期患者的毒性将较低。

公开(公告)号：US5277772A

公开(公告)日：1994-01-11

申请号：US692083

申请日：1991-04-26

Applicant: Mark A. Harmer

Inventor： Mark A. Harmer

IPC: C03C17/28 ,  C03C23/00 ,  C08F8/30 ,  D06M13/252 ,  D06M13/355 ,  D06M23/00 ,  G01N33/543 ,  G03C1/695 ,  G03F7/012 ,  G03F7/20 ,  C07D201/00

CPC classification number: D06M13/252 ,  C03C17/28 ,  C03C23/0015 ,  C08F8/30 ,  D06M13/355 ,  D06M23/005 ,  G01N33/54353 ,  G03C1/695 ,  G03F7/012 ,  G03F7/2041

Abstract: The invention concerns a method for the chemical modification of a surface based on the reaction of photolytically generated reactive intermediates derived from azido heterocycles with said surface.

Abstract translation: 本发明涉及一种用于基于衍生自叠氮基杂环的光解产生的反应中间体与所述表面的反应来化学修饰表面的方法。

公开(公告)号：US4338262A

公开(公告)日：1982-07-06

申请号：US180275

申请日：1980-08-21

Applicant: Otto Schallner ,  Siegfried Oeckl ,  Karl H. Schundehutte

Inventor： Otto Schallner ,  Siegfried Oeckl ,  Karl H. Schundehutte

IPC: C07C317/44 ,  C07C67/00 ,  C07C313/00 ,  C07C317/00 ,  C07C317/04 ,  C07C317/14 ,  C07D201/00 ,  C07C147/02 ,  C07C147/06

CPC classification number: C07C317/00

Abstract: Acid halides and anhydrides of acids of the formula ##STR1## with the substituent definitions given in the description are obtained by reacting the corresponding acids with organic or inorganic acid halides or acid anhydrides. The new compounds are intermediate products for the preparation of new reactive dyestuffs.

Abstract translation: 通过使相应的酸与有机或无机酰卤或酸酐反应，得到具有本说明书中给出的取代基定义的式“IMAGE”的酸的酰卤和酸酐。 新化合物是用于制备新的活性染料的中间产物。

公开(公告)号：US3991115A

公开(公告)日：1976-11-09

申请号：US633208

申请日：1975-11-19

Applicant: Richard Lynn Purgason

Inventor： Richard Lynn Purgason

IPC: C07D201/04 ,  C07D201/00 ,  C07C131/04

CPC classification number: C07C249/08

Abstract: This invention relates to a process for the production of cyclohexanone oxime by reacting cyclohexanone with excess aqueous hydroxylamine in the presence of excess ammonia. More specifically, the invention relates to improving yields of the oxime while reducing undesirable by-product formation by use of two or more stages of reaction with correlated adjustment of reaction conditions in each stage. The invention also involves improved recovery of the unreacted hydroxylamine reactant for recycle in the process.

Abstract translation: 本发明涉及通过在过量氨的存在下使环己酮与过量的羟胺反应生产环己酮肟的方法。 更具体地说，本发明涉及提高肟的产率，同时通过使用两阶段或更多阶段的反应，同时在每个阶段的反应条件的相关调整来减少不希望的副产物形成。 本发明还涉及在该方法中回收未反应的羟胺反应物以进行再循环。

公开(公告)号：US2960499A

公开(公告)日：1960-11-15

申请号：US76912358

申请日：1958-10-23

Applicant: STAMICARBON

Inventor： BOON JOHANNES W P

IPC: C07D201/00 ,  C07D201/16

CPC classification number: C07D201/16 ,  C07D201/00

公开(公告)号：US11767330B2

公开(公告)日：2023-09-26

申请号：US17858875

申请日：2022-07-06

Applicant: Foghorn Therapeutics Inc.

Inventor： Chong-Hui Gu ,  Joshua D. Waetzig

IPC: C07D519/00 ,  C07D201/00 ,  A61K31/4545

CPC classification number: C07D519/00 ,  C07B2200/13

Abstract: The present disclosure features citrate salts and pharmaceutical compositions useful for the treatment of BAF complex-related disorders. Also disclosed are methods for preparing compounds.

公开(公告)号：US20230101009A1

公开(公告)日：2023-03-30

申请号：US17991558

申请日：2022-11-21

Applicant: Mayo Foundation for Medical Education and Research ,  Regents of the University of Minnesota

Inventor： Michael P. Fautsch ,  Peter Dosa ,  Michael A. Walters ,  Gunda I. Georg

IPC: C07K5/062 ,  C07D405/04 ,  C07D405/12 ,  C07D285/24 ,  A61K31/549 ,  A61K31/454 ,  A61K31/4025 ,  A61K9/00 ,  A61K31/675 ,  A61K31/4439 ,  C07D201/00 ,  A61K31/353 ,  C07D311/20 ,  C07D311/70 ,  C07D405/14 ,  C07F9/6547 ,  C07F9/6558

Abstract: The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.

公开(公告)号：US10981951B2

公开(公告)日：2021-04-20

申请号：US15113773

申请日：2015-01-30

Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH ,  Regents of the University of Minnesota

Inventor： Michael P. Fautsch ,  Peter Dosa ,  Michael A. Walters ,  Gunda I. Georg

IPC: C07D311/20 ,  A61K9/51 ,  C07K5/062 ,  C07D405/04 ,  C07D405/12 ,  C07D285/24 ,  A61K31/549 ,  A61K31/454 ,  A61K31/4025 ,  A61K9/00 ,  A61K31/675 ,  A61K31/4439 ,  C07D201/00 ,  A61K31/353 ,  C07D311/70 ,  C07D405/14 ,  C07F9/6547 ,  C07F9/6558

Abstract: The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.

公开(公告)号：US09840512B2

公开(公告)日：2017-12-12

申请号：US14767815

申请日：2014-02-20

Applicant: Merck Sharp & Dohme Corp.

Inventor： Linda L. Brockunier ,  Helen Chen ,  Harry R. Chobanian ,  Matthew J. H. Clements ,  Alejandro Crespo ,  Duane E. DeMong ,  Yan Guo ,  William K. Hagmann ,  Karen M. Marcantonio ,  Michael Miller ,  Barbara Pio ,  Christopher W. Plummer ,  Dong Xiao

IPC: C07D311/04 ,  C07D311/28 ,  C07D491/052 ,  C07D493/04 ,  C07D201/00 ,  C07D405/14 ,  C07D319/20 ,  C07D405/04 ,  C07D405/06 ,  C07D405/10 ,  C07D413/10 ,  C07D417/04 ,  C07D491/048 ,  A61K31/352 ,  A61K31/416 ,  A61K31/422 ,  A61K31/427 ,  A61K31/436 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/497 ,  A61K31/538 ,  A61K45/06

CPC classification number: C07D493/04 ,  A61K31/352 ,  A61K31/416 ,  A61K31/422 ,  A61K31/427 ,  A61K31/436 ,  A61K31/4433 ,  A61K31/444 ,  A61K31/497 ,  A61K31/538 ,  A61K45/06 ,  C07D201/00 ,  C07D311/04 ,  C07D311/28 ,  C07D319/20 ,  C07D405/04 ,  C07D405/06 ,  C07D405/10 ,  C07D405/14 ,  C07D413/10 ,  C07D417/04 ,  C07D491/048 ,  C07D491/052

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

公开(公告)号：US20050085652A1

公开(公告)日：2005-04-21

申请号：US10821473

申请日：2004-04-08

Applicant: Wei Chen ,  Premchandran Ramiya ,  Ronald Burch ,  Richard Carter ,  Timothy Anderson ,  Sharon McIlvain ,  Heping Zhang

Inventor： Wei Chen ,  Premchandran Ramiya ,  Ronald Burch ,  Richard Carter ,  Timothy Anderson ,  Sharon McIlvain ,  Heping Zhang

IPC: A61K31/05 ,  A61K31/16 ,  A61K31/165 ,  A61K31/5415 ,  A61K31/551 ,  A61K45/06 ,  C07C51/36 ,  C07C231/02 ,  C07C233/20 ,  C07D201/00

CPC classification number: C07C231/02 ,  A61K31/05 ,  A61K31/16 ,  A61K31/165 ,  A61K31/5415 ,  A61K31/551 ,  A61K45/06 ,  C07C51/36 ,  A61K2300/00 ,  C07C57/03 ,  C07C233/20

Abstract: The present invention provides methods for synthesizing the trans isomer of capsaicin and/or capsaicin-like compounds by utilizing a process wherein the trans geometry is set from the beginning of the synthesis reaction and carried through the entire synthesis process.

Abstract translation: 本发明提供了通过利用反应几何形式从合成反应开始设定并通过整个合成过程进行的方法来合成辣椒素和/或辣椒素样化合物的反式异构体的方法。